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β1-AR polymorphisms and  
cardiac phenotype
The β-ARs are members of the G protein–
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well-documented  polymorphisms  that 
exist in human populations. The coding 
































The effect of the β1-AR Gly389Arg polymorphism on signal transduction and beta blockade by carvedilol. The Gly389Arg polymorphism of the 
β1-AR occurs in the region between the seventh transmembrane domain and the intracellular tail of the receptor (R and G correspond to arginine 
and glycine, respectively, at position 389 of the receptor). This highly conserved region is putatively associated with coupling to the Gs protein. 
The change of the amino acid residue at position 389 of the β1-AR from the polar, basic arginine (upper 3 panels) to the small, nonpolar glycine 
(lower 3 panels) may result in a modified structure that could alter receptor-Gs interaction. This region of the cytoplasmic tail of the receptor 
may participate in regulating the affinity of the receptor-Gs interaction. This could potentially explain the differences in receptor-Gs coupling and 
cAMP production associated with the Arg389 β1-AR variant as compared with the Gly389 β1-AR variant reported previously (7, 8). Under basal 
conditions, the Arg389 variant has been associated with increased cAMP production, which is markedly augmented as compared with the Gly389 
variant following agonist stimulation (7). This effect could also be attributed to a more favorable structural environment for interaction with Gs. 
Carvedilol treatment induces a conformational change resulting in the intracellular tail of the receptor being positioned more closely to the third 
intracellular loop; this inverse agonism of the receptor in theory would lead to decreased Gs coupling and reduced cAMP accumulation. Both 
variants demonstrated inverse agonist properties in response to carvedilol; however, the effect was increased 2.5-fold in the Arg389 variant, 
apparently due to conformation of the Arg389 structure in the presence of the ligand as observed by Rochais et al. in this issue of the JCI (14).
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measured by 35S-GTP binding and slightly 































cardiotoxicity  and  cardiac  pathology 
(3).  This  partially  explains  the  clinical 

























































authors  then  tagged  these  regions  with 
cerulean and yellow fluorescent proteins, 




























































































































Address  correspondence  to:  Walter  J. 
Koch, Center for Translational Medicine, 
George Zallie and Family Laboratory for 











tors: in silico drug discovery in 3D. Proc. Natl. Acad. 










rate. Am. J. Hum. Genet. 70:935–942.
  6. Small, K.M., McGraw, D.W., and Liggett, S.B. 2003. 
Pharmacology and physiology of human adrener-









tional recovery after ischemic injury. Am. J. Physiol. 
























with  chronic  heart  failure.  N. Engl. J. Med. 
344:1358–1364.
  16. Bond, R.A., and Ijzerman, A.P. 2006. Recent devel-










tions and implications. Expert opin. Pharmacother. 
11:1417–1427.
Macrophage heterogeneity and tissue lipids
Siamon Gordon





























motif  chemokine  receptor  1  (CX3CR1, 
also known as the fractalkine receptor) to 
enter atherosclerotic plaques. They also 
exploited an mAb, Gr-1, directed against 
Ly-6 family antigens to distinguish mono-
cyte subsets and used CD11c, a β2 integrin 
expressed by myeloid DCs and selected tis-
Nonstandard	abbreviations	used: CCR2, C-C motif 
chemokine receptor 2; CX3CR1, C-X3-C motif chemo-
kine receptor 1.
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